

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.\**



北京市春立正達醫療器械股份有限公司

**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1858)**

## **INSIDE INFORMATION**

### **PROGRESS OF THE PARTICIPATION IN THE STRATEGIC ALLOTMENT UNDER THE A SHARE OFFERING BY CONNECTED PERSONS UNDER THE SHARE OFFERING**

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcements dated 18 October 2021 and 6 December 2021 and the circular dated 19 November 2021 of the Company in relation to the Strategic Allotment to the Collective Assets Management Plan under the A Share Offering. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcement and circular. As approved by the EGM of the Company held on 6 December 2021, the Company may allot no more than 3,842,800 A Shares to its senior management and core employees through the Collective Assets Management Plan in accordance with the Strategic Allotment Plan under the A Share Offering.

The Board is pleased to announce that the Company has determined the final number of A Shares allotted to the Participants via the Collective Assets Management Plan in accordance with the Strategic Allotment Plan under the A Share Offering on 20 December 2021 is 3,615,601 A Shares, and details of the participation in the Strategic Allotment under the A Share Offering by the Participants through the Collective Assets Management Plan are as follows:

Name	Designation	Actual contribution amount (in RMB'000)	Approximate percentage of the actual contribution amount in the Collective Assets Management Plan	Approximate number of Shares calculated based on the approximate percentage of the actual contribution amount in the Collective Assets Management Plan	Approximate percentage of the number of Shares under the A Share Offering
Yue Shujun	Director and Deputy General Manager	27,550	25.43%	919,588	2.39%
Shi Chunbao	Chairman of the Board, Director, General Manager and Chief Engineer	26,600	24.56%	887,878	2.31%
Xie Feng Bao	Director and Deputy Chief Engineer	3,400	3.14%	113,488	0.30%
Wang Jianliang	Deputy General Manager	3,750	3.46%	125,171	0.33%
Zhai Zhiyong	Deputy General Manager	3,500	3.23%	116,826	0.30%
<b>Sub-total</b>		<b>64,800</b>	<b>59.82%</b>	<b>2,162,951</b>	<b>5.63%</b>
	Other senior management and core employees of the Group	43,520	40.18%	1,452,650	3.78%
<b>Total</b>		<b>108,320</b>	<b>100.00%</b>	<b>3,615,601</b>	<b>9.41%</b>

Note:

- The Participants do not directly hold the A Shares, but they hold the A Shares through their interests under the Collective Assets Management Plan. The above is the calculation of the number of shares to be allotted to the Collective Assets Management Plan and the amount subscribed by each of the Participant and is for illustrative purpose only.
- Certain figures in the above table have been subject to rounding adjustments or have been rounded to two decimal places. Any discrepancies between the total shown and sum of amounts listed are due to rounding.

**The Company will keep the shareholders and potential investors informed of any further development in relation to the A Share Offering in accordance with the Listing Rules and applicable laws and regulations. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and should consult their own professional advisors if they are in doubt.**

By order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
**Shi Chunbao**  
*Chairman*

Beijing, the PRC, 29 December 2021

*As at the date of this announcement, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.*

*\* For identification purpose only*